Author:
Gamblin T. Clark,Egorin Merrill J.,Zuhowski Eleanor G.,Lagattuta Theodore F.,Herscher Laurie L.,Russo Angelo,Libutti Steven K.,Alexander H. Richard,Dedrick Robert L.,Bartlett David L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference34 articles.
1. Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413
2. Dedrick RL (1986) Interspecies scaling of regional drug delivery. J Pharm Sci 75(11):1047–1052
3. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3):1–6
4. Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11
5. Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC (2000) Pharmacokinetics of gemcitabine and 2′, 2′-difluorodexoyrindine in patient with ascites. Pharmacotherapy 20(10):1204–1207